Brokers Set Expectations for AGIO FY2027 Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Zacks Research issued their FY2027 earnings per share (EPS) estimates for shares of Agios Pharmaceuticals in a research report issued to clients and investors on Thursday, March 6th. Zacks Research analyst A. Chakraborty anticipates that the biopharmaceutical company will post earnings of ($3.85) per share for the year. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.85) per share.

Several other equities research analysts have also recently commented on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Scotiabank lifted their target price on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research note on Monday, December 9th. Royal Bank of Canada lifted their target price on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. HC Wainwright initiated coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a “buy” rating and a $58.00 target price for the company. Finally, StockNews.com cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $56.57.

Agios Pharmaceuticals Stock Up 0.1 %

AGIO opened at $33.98 on Friday. The firm has a market capitalization of $1.95 billion, a P/E ratio of 3.00 and a beta of 0.88. The stock’s 50 day moving average price is $33.82 and its two-hundred day moving average price is $42.48. Agios Pharmaceuticals has a 12-month low of $27.14 and a 12-month high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%.

Insider Activity at Agios Pharmaceuticals

In other news, insider Tsveta Milanova sold 2,804 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the transaction, the insider now directly owns 18,906 shares in the company, valued at $608,395.08. The trade was a 12.92 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.93% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in AGIO. GF Fund Management CO. LTD. bought a new stake in shares of Agios Pharmaceuticals during the 4th quarter worth $39,000. Frazier Life Sciences Management L.P. lifted its holdings in shares of Agios Pharmaceuticals by 2.5% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 1,069,754 shares of the biopharmaceutical company’s stock worth $35,152,000 after acquiring an additional 25,600 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Agios Pharmaceuticals by 8.5% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 122,835 shares of the biopharmaceutical company’s stock valued at $4,036,000 after acquiring an additional 9,606 shares during the last quarter. Voloridge Investment Management LLC raised its holdings in Agios Pharmaceuticals by 2.1% during the 4th quarter. Voloridge Investment Management LLC now owns 200,481 shares of the biopharmaceutical company’s stock valued at $6,588,000 after buying an additional 4,082 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in Agios Pharmaceuticals during the 4th quarter valued at $5,337,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.